Taysha Gene Therapies, Inc. (TSHA)
| Market Cap | 1.71B +330.5% |
| Revenue (ttm) | 7.47M +3.4% |
| Net Income | -129.88M |
| EPS | -0.38 |
| Shares Out | 287.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,250,658 |
| Open | 6.16 |
| Previous Close | 6.30 |
| Day's Range | 5.81 - 6.24 |
| 52-Week Range | 2.25 - 7.30 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 11.63 (+95.13%) |
| Earnings Date | May 6, 2026 |
About TSHA
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-... [Read more]
Financial Performance
In 2025, Taysha Gene Therapies's revenue was $9.77 million, an increase of 17.28% compared to the previous year's $8.33 million. Losses were -$109.00 million, 22.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TSHA stock is "Strong Buy." The 12-month stock price target is $11.63, which is an increase of 95.13% from the latest price.
News
Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)
“We continued to execute our clinical development strategy for TSHA-102 and recently reaffirmed alignment with the FDA on our pathway to a BLA filing, including trial design, endpoints and the…
Taysha Gene Therapies Earnings Call Transcript: Q1 2026
TSHA-102 clinical and regulatory progress continued, with pivotal trial dosing on track for Q2 2026 and strong FDA alignment on BLA submission scenarios. Financials reflect increased R&D investment, and market research shows high demand for gene therapy with preference for intrathecal delivery.
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-ba...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-ba...
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-...
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TS...
Unusually active option classes on open April 16th
Unusual total active option classes on open include: Taysha Gene Therapies (TSHA), Energy Vault Holdings (NRGV), New Era Energy & Digital Inc (NUAI), Netflix (NFLX), Hims and Hers Health (HIMS),…
Taysha Gene Therapies price target raised to $17 from $14 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Taysha Gene Therapies (TSHA) to $17 from $14 and keeps a Buy rating on the shares. The firm said the…
Taysha Gene Therapies Earnings Call Transcript: Q4 2025
Significant clinical, regulatory, and commercial progress was made in 2025, highlighted by positive TSHA-102 data, FDA Breakthrough Therapy designation, and strong financial positioning with $319.8M in cash. Pivotal and ASPIRE trials are on track, with commercial readiness advancing.
Taysha Gene Therapies reports 2025 EPS (34c), consensus (34c)
Reports Q4 revenue $9.77M, consensus $6.3M. As of December 31, 2025, Taysha had $319.8M in cash and cash equivalents. Expects current cash resources will be sufficient to fund planned operating…
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026
Taysha Gene Therapies management to meet with Cantor
Meeting to be held in San Francisco on March 23 and in Denver on March 24 hosted by Cantor.
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-...
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
Taysha Gene Therapies (TSHA) announced that, on March 2, 2026, the Compensation Committee of Taysha’s Board of Directors granted one new employee restricted stock units representing 156,870 shares of ...
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
Taysha Gene Therapies (TSHA) announced that, on February 2, 2026, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, restricted stock units repres...
Taysha Gene Therapies announces progress across TSHA-102
Taysha Gene Therapies (TSHA) announced progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy with disease modifying potential, in clinical evaluation for the treat...
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to
Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo
Wells Fargo analyst Zachary Fadem raised the firm’s price target on Taysha Gene Therapies (TSHA) to $11 from $8 and keeps an Overweight rating on the shares. The firm sees…
Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs
Goldman Sachs analyst Salveen Richter moved its rating on Taysha Gene Therapies (TSHA) to Buy with an $11 price target from Early-Stage Biotech designation. The firm is positive on the…
Taysha price target raised to $19 from $13 at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies (TSHA) to $19 from $13 and keeps an Overweight rating on the shares. Published first on…
Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP
Citizens JMP raised the firm’s price target on Taysha Gene Therapies (TSHA) to $8 from $6 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported Q3 results…
Taysha Gene Therapies files automatic mixed securities shelf
08:32 EST Taysha Gene Therapies (TSHA) files automatic mixed securities shelf
Taysha Gene Therapies Earnings Call Transcript: Q3 2025
FDA breakthrough therapy designation and regulatory alignment position TSHA-102 for accelerated pivotal trial execution and BLA submission. Strong clinical data, regained global rights, and a solid cash position support late-stage development and commercialization.
Taysha Gene Therapies reports Q3 EPS (9c), consensus (9c)
Reports Q3 revenue $0, consensus $1.38M. “The progress we’ve made in the third quarter of 2025 sets the stage for a potentially transformative period ahead for Taysha. We recently received…